Seeking Alpha
04 Nov 2026, 10:46 UTC · 1h ago
Eli Lilly: Higher Volume, Lower Realized Prices
Impact · against what's priced in
The news is neutral to slightly negative for LLY as strong volume growth is offset by structural pricing erosion. While revenue growth remains robust, the 15% decline in realized prices validates the bear case regarding margin compression and challenges the sustainability of the high growth rates the market currently assumes.
- LLY−0.20
Challenges what's priced in
- The price assumes
The bear case that GLP-1 concentration risk and competitive pressure from Novo Nordisk's oral Wegovy will compress margins
The 15% decline in realized prices provides concrete evidence for the margin compression risks the market had previously declined to price in, suggesting that volume growth alone may not sustain the required 30.2% long-term CAGR.
What LLY's price assumes · Sep 10
